COVID-19

Views & Analysis

How necessity is driving the ‘inevitable transformation’ of ...

From virtual conferences to CPD webinars, medical education moved online when COVID-19 hit. But is this new way of learning here to stay?

News

Gilead finally breaks its silence on remdesivir’s price

After weeks of speculation, Gilead Sciences has revealed its pricing plans for coronavirus drug remdesivir – and the rationale behind its decision.

Views & Analysis

The real impact of COVID-19 on emerging markets

When COVID-19 began to spread uncontrollably, numbers of confirmed cases initially grew most quickly in developed economies across China, Europe and then the US.

News

COVID-19 drug remdesivir recommended for EU approval

The EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation to Gilead’s COVID-19 treatment remdesivir – making it the first drug of its kind to be g

Views & Analysis